Schulich school of Medicine and Dentistry logo Gastroenterology Schulich School of Medicine & Dentistry

Brian Feagan

Brian Feagan

Contact Information

Robarts Clinical Trials
Dundas St., London, Ontario

Executive Assistants:
Lesley McLellan
and Heather Carter
Tel: 519.931.5289 or 519.858.5087

Research Interests/Specialization

Inflammatory Bowel Diseases
Clinical Trial Design and Management

Dr. Brian Feagan is a specialist in Internal Medicine, with training in clinical epidemiology and gastroenterology.  His research interests focus on the design and implementation of randomized controlled trials of therapy for inflammatory bowel disease, and he has been the principal investigator on numerous multi-centre trials evaluating new treatments for the disease.  Recently, Feagan has also begun to investigate the application of cluster randomization in the evaluation of health policies.  This methodology is well-suited to the assessment of the effectiveness of treatment programs, such as a care path for disease management. Dr. Feagan is a Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Director of Robarts Clinical Trials at Robarts Research Institute.

Selected Publications

Travis S, Feagan BG, Rutgeerts P, van Deventer S.  The Future of Inflammatory Bowel Disease Management: Combining Progress in Trial Design with Advances in Targeted Therapy.  J Crohns Colitis 2012 Feb; 6 Suppl2: S250-9

Feagan BG, Greenberg GR, Wild G, et al. Treatment of Active Crohn's Disease with MLN0002: A Humanized Antibody to the Alpha4Beta7 Integrin. Clinical Gastroenterology & Hepatology 2008; 6(12): 1370-7

Sandborn WJ, Feagan BG, Lichtenstein GR.  Medical Management of Mild to Moderate Crohn's Disease Evidence-Based Treatment Algorithms for Induction and Maintenance of Remission.  Ali Pharma & Thera 2007; 26(7): 987-1003

Feagan BG, Reinisch W, Rutgeerts P, et al.  The Effects of Infliximab Therapy on Health-related Quality of Life in Ulcerative Colitis Patients.  Am J Gastroenterol 2007 Aprl 102(4): 794-802

Sandborn WJ, Feagan BG, Stoinov S, et al.  Certolizumab Pegol for the Treatment of Crohn's Disease.  New Engl J Med 2007: 357(3): 228-238

Rutgeerts P, Sandborn WJ, Feagan BG, et al.  Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis.  New Engl J Med 2005: 353(23): 2462-2476

Feagan BG, Greenberg GR, Wild G, et al.  Treatment of Ulcerative Colitis with a Humanized Antibody to the Alpha4Beta7 Integrin.  New Engl J Med 2005: 352(24): 2499-2507

Hanauer SB, Feagan BG, Lichtenstein GR et al.  Maintenance Infliximab for Crohn's Disease: The ACCENT 1 Randomized Trial.  Lancet 2002 (May 4): 359(9317): 1541-49

Feagan BG, Fedorak RN, Irvine EJ, et al.  A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease.  N Engl J Med 2000: 242(22): 11627-1632

Feagan BG, Rochon J, Irvine EJ, et al.  Methotrexate for the Treatment of Crohn's Disease.  New Engl J Med 1995; 332(5): 292-297